Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy. The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.

CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.

Part of Pfizer Inc., Apollon, Inc. is an American company located in Malvern, PA. The firm develops non viral DNA-based vaccines. It was founded by Vincent R. Zurawski. On May 11, 1998 Wyeth Corp., now a subsidiary of Pfizer Inc. acquired Apollon, Inc.

Commonwealth Scientific & Industrial Research Organisation provides scientific and industrial research services. It plays a role in collaboration within the Australian national innovation system and as an advisor to government, industry and the community. The company was founded in 1916 and is headquartered in Canberra, Australia.

Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases.

ABION, Inc. engages in the development of biopharmaceuticals for treating incurable diseases. Its products include protein, nucleic acid, and antibody therapeutics. The company was founded on April 16, 2007 and is headquartered in Seoul, South Korea.

Diversa Corporation is an industrial biotechnology company that develops high performance enzymes. It extracts microbial DNA directly from collected samples to avoid the often impossible task of growing microbes in the laboratory. It mines its collection of microbial genes, numbering in the billions, using high-throughput screening technologies designed to identify unique enzymes as product candidates. Diversa Corporation develops enzymes that are environmentally friendly and more cost-effective for industries such as the global food and fuel markets. It has developed enzymes  to meet the specific needs of companies in various markets, including grain processing, bio fuels, animal health and nutrition and other industries.

Secretary of State for Defence is a private company headquartered in the United Kingdom with subsidiaries in that country. The firm operates as a state secretary of defense.

Suzhou Abogen Biosciences Co., Ltd. is a Chinese company located in Suzhou. The firm operates as a discovery stage biotechnology company that focuses on developing nucleic acid-based therapeutics. It was founded in 2019 by Bo Ying, who has been the CEO since that date.

Verenium Corporation was a San Diego, California-based industrial biotechnology company founded in 2007 as the result of a merger between Diversa (San Diego) and Celunol (Cambridge, MA). The company specialized in research and development for the production of high performance enzymes used in industrial applications, including biofuel generation, hydraulic fracturing. Verenium was acquired by BASF corporation in 2013. The company's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries including the global food and fuel markets.

Sino (Shenzhen) Biomedical Research Co., Ltd., established on 2017-11-14, Business scope includes general business items:Research and development of biotechnology(No restricted items).,The licensing program is: